share_log

BTIG Maintains Buy on MaxCyte, Raises Price Target to $11

Benzinga Real-time News ·  Aug 15, 2022 07:04

BTIG analyst Mark Massaro maintains MaxCyte (NASDAQ:MXCT) with a Buy and raises the price target from $10 to $11.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment